In the United States<unk>  is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. In the European Union<unk>  is indicated for the treatment of relapsing remitting multiple sclerosis in adults.
Peginterferon beta-1a
Peginterferon alfa-2a
Peginterferon alfa-2b
Ropeginterferon alfa-2b
Pegylated interferon
Interferon beta-1b
Interferon beta-1a
Ribavirin